Johnson & Johnson (0R34) Share Forecast & Price Target

Compare

60 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0R34 Analyst Ratings

Moderate Buy

12 Buy

7 Hold

0 Sell

Based on 19 analysts giving stock ratings to

Johnson

& Johnson

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0R34 Stock 12 Month Forecast

Average Price Target

$206.47

▲(9.25% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Johnson & Johnson in the last 3 months. The average price target is $206.47 with a high forecast of $225.00 and a low forecast of $176.00. The average price target represents a 9.25% change from the last price of $188.99.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"139":"$139","226":"$226","160.75":"$160.8","182.5":"$182.5","204.25":"$204.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":225,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$225.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":206.47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$206.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":176,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$176.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[139,160.75,182.5,204.25,226],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,185.89,188.89846153846153,191.90692307692308,194.9153846153846,197.92384615384614,200.9323076923077,203.94076923076923,206.94923076923075,209.9576923076923,212.96615384615384,215.9746153846154,218.9830769230769,221.99153846153845,{"y":225,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,185.89,187.47307692307692,189.05615384615385,190.63923076923075,192.22230769230768,193.8053846153846,195.38846153846154,196.97153846153844,198.55461538461537,200.1376923076923,201.72076923076924,203.30384615384614,204.88692307692307,{"y":206.47,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,185.89,185.12923076923076,184.36846153846153,183.6076923076923,182.84692307692308,182.08615384615385,181.32538461538462,180.56461538461537,179.80384615384614,179.0430769230769,178.28230769230768,177.52153846153846,176.76076923076923,{"y":176,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":156.986,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":155.727,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.037,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140.103,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":148.597,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":160.734,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":155.32,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":152.171,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.55,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.545,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.071,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.848,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.89,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$225.00

Average Price Target$206.47

Lowest Price Target$176.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Veda Pharmyne

TR | OpenAI - 4o

$217

Buy

14.82%

Upside

Reiterated

10/26/25

AI Generated ArticleAI Generated Article

Joanne Wuensch

Citi

$215

Buy

13.76%

Upside

Reiterated

10/21/25

Citi Remains a Buy on Johnson & Johnson (JNJ)

Vamil Divan

Guggenheim

$206

Buy

9.00%

Upside

Reiterated

10/19/25

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ) and Scholar Rock Holding (NASDAQ: SRRK)

David Risinger

Leerink Partners

$171→$201

Hold

6.35%

Upside

Reiterated

10/16/25

Johnson & Johnson (JNJ) Gets a Hold from Leerink Partners

Tim Anderson

Bank of America Securities

$198→$204

Hold

7.94%

Upside

Reiterated

10/15/25

Hold Recommendation for Johnson & Johnson Amid Modest Earnings Beat and Strategic Spin-Off Plans

Jayson Bedford

Raymond James

$174→$209

Buy

10.59%

Upside

Reiterated

10/15/25

Johnson & Johnson price target raised to $209 from $174 at Raymond JamesJohnson & Johnson price target raised to $209 from $174 at Raymond James

Terence Flynn

Morgan Stanley

$178→$190

Hold

0.53%

Upside

Reiterated

10/15/25

Balanced Outlook on Johnson & Johnson: Hold Rating Amid Strategic Shifts and Uncertainties

Matt Miksic

Barclays

$176

Hold

-6.87%

Downside

Reiterated

10/15/25

Barclays Sticks to Its Hold Rating for Johnson & Johnson (JNJ)

Larry Biegelsen

Wells Fargo

$212

Buy

12.18%

Upside

Reiterated

10/15/25

Danielle Antalffy

UBS

$190→$214

Buy

13.23%

Upside

Reiterated

10/15/25

Johnson & Johnson price target raised to $214 from $190 at UBSJohnson & Johnson price target raised to $214 from $190 at UBS

Chris Schott

J.P. Morgan

$195→$205

Hold

8.47%

Upside

Reiterated

10/15/25

J.P. Morgan Sticks to Its Hold Rating for Johnson & Johnson (JNJ)JPMorgan raised its price target on Johnson Johnson (NYSE: JNJ) to $205.00 (from $195.00) while maintaining a Neutral rating.

Rick Wise

Stifel Nicolaus

$165→$190

Hold

0.53%

Upside

Reiterated

10/15/25

Johnson & Johnson price target raised to $190 from $165 at StifelJohnson & Johnson price target raised to $190 from $165 at Stifel

Alexandria Hammond

Wolfe Research

$200→$225

Buy

19.05%

Upside

Reiterated

10/15/25

Johnson & Johnson (JNJ) Receives a Buy from Wolfe Research

David Toung

Argus Research

$185→$210

Buy

11.12%

Upside

Reiterated

10/14/25

Argus Research Sticks to Their Buy Rating for Johnson & Johnson (JNJ)

Stewart Glickman

CFRA

$220

Buy

16.41%

Upside

Upgraded

10/14/25

Positive Report for Johnson & Johnson (JNJ) from CFRA

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Veda Pharmyne

TR | OpenAI - 4o

$217

Buy

14.82%

Upside

Reiterated

10/26/25

AI Generated ArticleAI Generated Article

Joanne Wuensch

Citi

$215

Buy

13.76%

Upside

Reiterated

10/21/25

Citi Remains a Buy on Johnson & Johnson (JNJ)

Vamil Divan

Guggenheim

$206

Buy

9.00%

Upside

Reiterated

10/19/25

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ) and Scholar Rock Holding (NASDAQ: SRRK)

David Risinger

Leerink Partners

$171→$201

Hold

6.35%

Upside

Reiterated

10/16/25

Johnson & Johnson (JNJ) Gets a Hold from Leerink Partners

Tim Anderson

Bank of America Securities

$198→$204

Hold

7.94%

Upside

Reiterated

10/15/25

Hold Recommendation for Johnson & Johnson Amid Modest Earnings Beat and Strategic Spin-Off Plans

Jayson Bedford

Raymond James

$174→$209

Buy

10.59%

Upside

Reiterated

10/15/25

Johnson & Johnson price target raised to $209 from $174 at Raymond JamesJohnson & Johnson price target raised to $209 from $174 at Raymond James

Terence Flynn

Morgan Stanley

$178→$190

Hold

0.53%

Upside

Reiterated

10/15/25

Balanced Outlook on Johnson & Johnson: Hold Rating Amid Strategic Shifts and Uncertainties

Matt Miksic

Barclays

$176

Hold

-6.87%

Downside

Reiterated

10/15/25

Barclays Sticks to Its Hold Rating for Johnson & Johnson (JNJ)

Larry Biegelsen

Wells Fargo

$212

Buy

12.18%

Upside

Reiterated

10/15/25

Danielle Antalffy

UBS

$190→$214

Buy

13.23%

Upside

Reiterated

10/15/25

Johnson & Johnson price target raised to $214 from $190 at UBSJohnson & Johnson price target raised to $214 from $190 at UBS

Chris Schott

J.P. Morgan

$195→$205

Hold

8.47%

Upside

Reiterated

10/15/25

J.P. Morgan Sticks to Its Hold Rating for Johnson & Johnson (JNJ)JPMorgan raised its price target on Johnson Johnson (NYSE: JNJ) to $205.00 (from $195.00) while maintaining a Neutral rating.

Rick Wise

Stifel Nicolaus

$165→$190

Hold

0.53%

Upside

Reiterated

10/15/25

Johnson & Johnson price target raised to $190 from $165 at StifelJohnson & Johnson price target raised to $190 from $165 at Stifel

Alexandria Hammond

Wolfe Research

$200→$225

Buy

19.05%

Upside

Reiterated

10/15/25

Johnson & Johnson (JNJ) Receives a Buy from Wolfe Research

David Toung

Argus Research

$185→$210

Buy

11.12%

Upside

Reiterated

10/14/25

Argus Research Sticks to Their Buy Rating for Johnson & Johnson (JNJ)

Stewart Glickman

CFRA

$220

Buy

16.41%

Upside

Upgraded

10/14/25

Positive Report for Johnson & Johnson (JNJ) from CFRA

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Johnson & Johnson

1 Month

xxx

Success Rate

16/26 ratings generated profit

Average Return

+1.27%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.54% of your transactions generating a profit, with an average return of +1.27% per trade.

3 Months

xxx

Success Rate

23/26 ratings generated profit

Average Return

+4.50%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 88.46% of your transactions generating a profit, with an average return of +4.50% per trade.

1 Year

Danielle AntalffyUBS

Success Rate

25/26 ratings generated profit

Average Return

+9.92%

reiterated a buy rating 21 days ago

Copying Danielle Antalffy's trades and holding each position for 1 Year would result in 96.15% of your transactions generating a profit, with an average return of +9.92% per trade.

2 Years

xxx

Success Rate

21/21 ratings generated profit

Average Return

+26.80%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +26.80% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0R34 Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0R34 has received 27 Buy Ratings, 17 Hold Ratings, and 0 Sell Ratings. 0R34 average Analyst price target in the past 3 months is 206.47.

Each month's total comprises the sum of three months' worth of ratings.

0R34 Financial Forecast

0R34 Earnings Forecast

Next quarter’s earnings estimate for 0R34 is $2.54 with a range of $2.48 to $2.58. The previous quarter’s EPS was $2.80. 0R34 beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year 0R34 has Preformed in-line its overall industry.

0R34 Sales Forecast

Next quarter’s sales forecast for 0R34 is $24.15B with a range of $24.04B to $24.48B. The previous quarter’s sales results were $23.99B. 0R34 beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 0R34 has Preformed in-line its overall industry.

0R34 Stock Forecast FAQ

What is GB:0R34’s average 12-month price target, according to analysts?

Based on analyst ratings, Johnson & Johnson’s 12-month average price target is 206.47.

What is GB:0R34’s upside potential, based on the analysts’ average price target?

Johnson & Johnson has 9.25% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Johnson & Johnson a Buy, Sell or Hold?

Johnson & Johnson has a consensus rating of Moderate Buy, which is based on 12 buy ratings, 7 hold ratings and 0 sell ratings.

What is Johnson & Johnson’s share price target?

The average share price target for Johnson & Johnson is 206.47. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $225.00 ,and the lowest forecast is $176.00. The average share price target represents 9.25% Increase from the current price of $188.99.

What do analysts say about Johnson & Johnson?

Johnson & Johnson’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of Johnson & Johnson?

To buy shares of GB:0R34, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Johnson & Johnson (0R34) Share Forecast & Price Target

0R34 Analyst Ratings

0R34 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Johnson & Johnson

0R34 Analyst Recommendation Trends

0R34 Financial Forecast

0R34 Earnings Forecast

0R34 Sales Forecast

0R34 Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts